EHA 2023 Congress
The European Hematology Association (EHA) 2023 Congress was held June 8-11, 2023, in Frankfurt, Germany. The meeting will highlight the latest updates on clinical research and practice in hematologic oncology and feature new developments in basic and translational research.
Advertisement
Advertisement
The NCRI AML18 trial evaluated the sequential addition of quizartinib to intensive chemotherapy in older adults with AML.
The “effect of gilteritinib was more pronounced” in patients who had detectable MRD than those who did not.
At a median follow-up of 55 weeks, 90% of patients completed 24 weeks of treatment and 56% completed 48 weeks of treatment.
The study included older patients with newly diagnosed Ph-negative CD22-positive B-lineage ALL.
Dr. Gagelmann outlines the challenges that he sees in Europe and across the globe for young researchers and clinicians.
The study showed that the infusion of obe-cel resulted in very low rates of Grade 3 or higher CRS and ICANS.
In this video interview from EHA, Dr, Munshi shares the close-out efficacy and safety results from CARTITUDE-1.
Dr. Gagelmann outlines key highlights of the session, his presentation and what he hopes attendees learned from the session.
A specific subset of antibiotics "were particularly bad" for the microbiome and were associated with poor survival.
The study included 300 patients with advanced MCL who did not have clinically significant comorbidities.
The trial included patients with PV who had at least three therapeutic phlebotomies in the 28 weeks prior to enrollment.
However, achieving a spleen volume reduction on the best available therapy was not linked with improved survival.
Dr. Mascarenhas and colleagues identified 11,371 patients with myelofibrosis, finding that 76.8% had concurrent anemia.
The median JAK2 mutant allele burden at baseline significantly differed among MPN subsets.
Dr. Kuykendall and colleagues presented their findings during the 2023 European Hematology Association Congress.
Dr. Krecak presented the research during the 2023 EHA Congress.
KER-050 is a modified activin receptor type IIA ligand trap designed to inhibit select TGF-β superfamily ligands.
Dr. Martin discusses key updates in multiple myeloma from ASCO, EHA, and the IMWG meetings.
The study evaluated imetelstat versus placebo in patients with lower-risk MDS who were highly transfusion dependent.
Dr. Stéphane De Botton discusses his EHA abstract on tamibarotene-based therapy in MDS/AML.
In this short from the 2023 EHA Congress, Dr. Brown talks about the genomic evolution of pirtobrutinib resistance.
Blood Cancers Today Associate Elias Jabbour, MD, gives an update from the 2023 EHA Congress.
Dr. Thijssen served as chair for the Young EHA session on senescence, aging, and cell death.
Dr. Lonial shares his top highlights in multiple myeloma from the EHA and ASCO meetings.
Dr. Garcia-Manero presented results from the phase III COMMANDS trial during the 2023 ASCO Meeting.
Dr. Dickinson discusses major updates to be presented during the 2023 European Hematology Association Congress.
Luspatercept-aamt demonstrated “favorable outcomes” compared with epoetin alfa across common mutations in MDS.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.